IGM Biosciences
Liqin Liu is a seasoned professional in the field of immuno-oncology research, currently serving as Sr Director of I-O Research at IGM Biosciences, Inc. since July 2021. Prior to this role, Liqin held the position of Head of Discovery and Translational Research at ASKGENE PHARMA, INC. from May 2019 to June 2021. Liqin's extensive experience also includes serving as Associate Director at MacroGenics, Inc. from January 2013 to April 2019, and Senior Scientist and Scientist II roles at Amgen between January 2004 and December 2011, as well as Scientist II at ViaCell from January 2000 to January 2004. Liqin Liu earned a PhD in Molecular and Cellular Biology and Biochemistry from the Medical College of Ohio, completing the degree in January 1996.
This person is not in any teams
This person is not in any offices
IGM Biosciences
1 followers
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.